Clinical trial · Observational
Radiotherapy in Primary Mediastinal Lymphoma
Adjuvant Radiotherapy in Primary Mediastinal Lymphoma in Patients That Received R-CHOP
NCT01230008CI-TRIAL-00004069pmlcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The use of Rituximab has been proposed to be useful and avoid the use of radiotherapy in diffuse large B-cell lymphoma with bulky disease.We assess efficacy of adjuvant radiotherapy in patients treated with R-CHOP
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adjuvant Radiotherapy on Complete Remission Patients | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| no drugs | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Radiotherapy in mediastinal lymphoma
- description
- Adjuvant radiotherapy or not (control group) in patients treated with R-CHOP
- label
- Radiotherapy in mediastinal lymphoma
- description
- Radiotherapy will no be administered in patients treated with R-CHOP
- label
- Radiotherapy in primary mediastinal lymphoma
- description
- Patients with primary mediastinal lymphoma will be treated with R-CHOP as induction therapy, if complete response is achieved, they were allocated to received or no (control group) adjuvatn radiotherapy, 3.5 G to mediastinal site.
- interventionNames
- Radiation: no drugs
Primary outcomes (1)
- measure
- measurement of progression free-survival and overall survival at > 5 years
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: Diagnosis of primary mediastinal lymphoma No previous treatment performance status \< 2 HIV, Hepatis B and C negative Normal :Renal, hepatic, pulmonary and cardiac function Exclusion Criteria: pregnancy \-
References
Publications (0)
Data not yet available
No reference posted for this study.